Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CAO Sells $11,160.60 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREGet Rating) CAO Theodore Alan Huizenga sold 132 shares of the firm’s stock in a transaction dated Saturday, April 16th. The shares were sold at an average price of $84.55, for a total transaction of $11,160.60. Following the completion of the sale, the chief accounting officer now owns 16,914 shares of the company’s stock, valued at approximately $1,430,078.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of NASDAQ RARE traded up $1.17 during trading on Tuesday, hitting $79.61. 3,980 shares of the company traded hands, compared to its average volume of 437,963. Ultragenyx Pharmaceutical Inc. has a 1 year low of $61.21 and a 1 year high of $119.54. The stock has a 50-day moving average of $71.42. The company has a market cap of $5.52 billion, a price-to-earnings ratio of -11.69 and a beta of 1.68.

Ultragenyx Pharmaceutical (NASDAQ:RAREGet Rating) last announced its quarterly earnings data on Thursday, February 10th. The biopharmaceutical company reported ($1.79) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.47). Ultragenyx Pharmaceutical had a negative net margin of 129.20% and a negative return on equity of 44.24%. The company had revenue of $83.39 million for the quarter, compared to analysts’ expectations of $83.68 million. During the same period in the prior year, the firm earned ($1.34) earnings per share. The firm’s quarterly revenue was down 8.9% on a year-over-year basis. On average, equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.57 EPS for the current fiscal year.

A number of equities research analysts have recently issued reports on the stock. StockNews.com assumed coverage on shares of Ultragenyx Pharmaceutical in a research report on Thursday, March 31st. They set a “hold” rating for the company. Credit Suisse Group upgraded shares of Ultragenyx Pharmaceutical from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $99.00 to $105.00 in a research report on Wednesday, March 16th. Zacks Investment Research upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating and set a $75.00 price target for the company in a research report on Tuesday, February 15th. JPMorgan Chase & Co. upgraded shares of Ultragenyx Pharmaceutical from a “neutral” rating to an “overweight” rating and set a $132.00 price target for the company in a research report on Friday, February 11th. Finally, Morgan Stanley reduced their price target on shares of Ultragenyx Pharmaceutical from $120.00 to $118.00 and set an “overweight” rating for the company in a research report on Friday, February 11th. One analyst has rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, Ultragenyx Pharmaceutical presently has an average rating of “Buy” and a consensus price target of $122.27.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP grew its stake in shares of Ultragenyx Pharmaceutical by 32.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 226,256 shares of the biopharmaceutical company’s stock valued at $20,401,000 after buying an additional 56,065 shares during the period. Allianz Asset Management GmbH lifted its holdings in shares of Ultragenyx Pharmaceutical by 133.6% during the 3rd quarter. Allianz Asset Management GmbH now owns 43,361 shares of the biopharmaceutical company’s stock valued at $3,911,000 after acquiring an additional 24,799 shares in the last quarter. State of New Jersey Common Pension Fund D lifted its holdings in shares of Ultragenyx Pharmaceutical by 6.5% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 42,132 shares of the biopharmaceutical company’s stock valued at $3,800,000 after acquiring an additional 2,562 shares in the last quarter. Virginia Retirement Systems ET AL lifted its holdings in shares of Ultragenyx Pharmaceutical by 13.0% during the 4th quarter. Virginia Retirement Systems ET AL now owns 13,900 shares of the biopharmaceutical company’s stock valued at $1,169,000 after acquiring an additional 1,600 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. acquired a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at $334,000. 97.52% of the stock is owned by institutional investors.

About Ultragenyx Pharmaceutical (Get Rating)

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII.

Featured Articles

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.